Here are four things to know:
1. SI-BONE booked $52 million in revenue for the 12 months ending June 30.
2. Morgan Stanley and Bank of America Merrill Lynch are the deal’s joint bookrunners.
3. Pricing terms were not disclosed.
4. SI-BONE develops the iFuse Implant System, a minimally invasive sacroiliac joint disorder treatment.
More articles on devices:
NuVasive welcomes CEO of Google, Johnson & Johnson partnership company to board
Medtronic adds to spine business with $1.64B acquisition of Mazor: 6 things to know
SpineEx files for $17M IPO: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
